Inhibition of STAT-1

Details Inhibition of STAT-1 Inhibition of STAT-1

2002-10-02

2009-02-03

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100

Reexamination Certificate

active

07485628

ABSTRACT:
The present invention relates to inhibitors of the transcription factor STAT-1, their use as therapeutic means as well as their use for the prevention or therapy of cardio-vascular complications like restenosis after percutaneous angioplasty or stenosis of venous bypasses, the graft versus host reaction, the ischemia/refusion-related damage in the context of surgical interventions and organ transplantation respectively, immunological hypersensitivity reactions, in particular the allergic rhinitis, the drug and food allergies, in particular urticaria and celiac disease (sprue), contact eczema and the immune complex diseases, in particular alveolitis, arthritis, glomerulonephritis and allergic vasculitis, inflammatory chondro- and osteopathies, in particular arthrosis, gout, ostitis and osteomyelitis, polyneuritis as well as acute and subacute respectively, infection contingent and in particular post-infectious inflammatory diseases, in particular bronchitis, endocarditis, hepatitis, myocarditis, nephritis, pericarditis, peritonitis and pancreatitis, including the septic shock.

REFERENCES:
patent: 5821053 (1998-10-01), Auron et al.
patent: 5883228 (1999-03-01), Darnell, Jr. et al.
patent: 2005/0192238 (2005-09-01), Hecker et al.
patent: WO 99/42571 (1999-08-01), None
patent: WO 01/01985 (2001-01-01), None
patent: WO 01/37821 (2001-05-01), None
Mann, M.J. and V.J. Dzau (2000). Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Invest., v.106, No. 9: 1071-1075.
Opalinska, J.B. and A.M. Gewirtz (2002). Nucleic-acid Therapeutics: Basic Principles and Recent Applications. Nature Reviews Drug Discovery, v.1:503-514.
Jen, et al. (2000) Suppression of Gene Expression by Targeted Disruption of Messenger RNA:□□Available Options and Current Strategies. Stem Cells, v.18:307-19.
Fujio et al., “Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac mycytes,”J. Clin. Invest., 99(12):2898-2905, 1997.
GenBank Accession No. NM007315. 1992.
GenBank Accession No. XM010893. 2002.
Huang et al., “Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-glycation end-product-induced cellular mitogenesis in NRK-49F cells,”Biochem. J., 342:231-238, 1999.
Lauth et al., “Transcriptional control of deformation-induced preproendothelin-1 gene expression in endothelial cells,”J. Mol. Med., 78:441, 2000.
Ohmori et al., “Synergy between interferon-γ and tumor necrosis factor-αin transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kB,”J. Biol. Chem., 272:14899, 1997.
Ricote et al., “The peroxisome proliferator-activated receptor-A is a negative regulator of macrophage activation,”Nature, 391(6662):79-82, 1998.
Rosenkranz-Weiss et al., “Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells,”J. Clin. Invest., 93:2236-2243, 1994.
Schieffer et al., “Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction,”Circ. Res., 87:1195, 2000.
Yokota et al., “Preferential and persistant activation of the STAT1 pathway in rheumatoid synovial fluid cells,”J. Rheumatol., 28(9):1952-1959, 2001.

Affiliated with

Also associated with

Rating

Inhibition of STAT-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of STAT-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of STAT-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128222